ACADIA Pharmaceuticals
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell ACAD and other ETFs, options, and stocks.About ACAD
ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
CEOCatherine Owen Adams
CEOCatherine Owen Adams
Employees654
Employees654
HeadquartersSan Diego, California
HeadquartersSan Diego, California
Founded1993
Founded1993
Employees654
Employees654
ACAD Key Statistics
Market cap3.64B
Market cap3.64B
Price-Earnings ratio16.38
Price-Earnings ratio16.38
Dividend yield—
Dividend yield—
Average volume2.62M
Average volume2.62M
High today$21.85
High today$21.85
Low today$21.32
Low today$21.32
Open price$21.80
Open price$21.80
Volume1.02M
Volume1.02M
52 Week high$26.65
52 Week high$26.65
52 Week low$13.40
52 Week low$13.40
ACAD News
Simply Wall St 3d
Will Acadia Pipeline Updates Reveal a Shift in Its Neurology Growth Strategy?Acadia Pharmaceuticals recently announced it will present a late-breaker oral platform and two poster presentations at the International Congress of Parkinson’s...
Simply Wall St 3d
A Look at Acadia Pharmaceuticals’s Valuation After Setback in Phase 3 Prader-Willi TrialAcadia Pharmaceuticals (ACAD) just shared results from its Phase 3 COMPASS PWS trial, with intranasal carbetocin missing both primary and secondary endpoints fo...
Analyst ratings
63%
of 19 ratingsBuy
63.2%
Hold
31.6%
Sell
5.3%
People also own
Based on the portfolios of people who own ACAD. This list is generated using Robinhood data, and it’s not a recommendation.